SCHEDULE 13G/A: Bleichroeder LP and Holdings Reaffirm 14.9% Stake in MDxHealth SA Through Latest SEC Filing
Beneficial Ownership Amendment
Bleichroeder LP and Bleichroeder Holdings LLC have filed an amendment to their Schedule 13G, confirming their beneficial ownership of 14.9% of MDxHealth SA's Ordinary Shares as of December 31, 2024.
Summary
- Bleichroeder LP and Bleichroeder Holdings LLC collectively report beneficial ownership of 7,378,333 Ordinary Shares of MDxHealth SA.
- This ownership represents 14.9% of the total 49,497,334 Ordinary Shares outstanding as reported by MDxHealth SA.
- Bleichroeder LP is classified as an Investment Adviser, and Bleichroeder Holdings LLC as a Parent Holding Company.
- Of the total shares, 4,014,216 shares, equating to 8.11% of the outstanding Common Stock, are held by 21 April Fund Ltd., for which Bleichroeder LP acts as investment adviser.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G/A) reporting beneficial ownership. It contains factual information about an investor's stake and does not convey positive or negative sentiment regarding the issuer's performance or outlook. The maintenance of a significant stake by an institutional investor could be seen as mildly positive, but the filing itself is neutral.
Positives
- A significant institutional investor, Bleichroeder LP, maintains a substantial stake (14.9%) in MDxHealth SA, potentially indicating continued confidence in the company.
- The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of influencing control, which can provide stability regarding the investor's intentions.
Future Outlook
Not applicable. This filing does not contain forward-looking statements or guidance from MDxHealth SA or the reporting persons regarding the issuer's future.
Industry Context
This filing is a routine disclosure of a significant ownership stake by an investment firm in a healthcare diagnostics company. It reflects an ongoing investment position rather than a new strategic move or industry trend.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, confirming their continued holding of 14.9% of the company's shares. This can offer some reassurance regarding institutional interest.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 02/13/2025 | Signature date of the Schedule 13G/A filing by Michael M. Kellen, Chairman and Co-CEO of Bleichroeder LP and Bleichroeder Holdings LLC. |
Keywords
MDxHealth SA, Bleichroeder LP, Bleichroeder Holdings LLC, Schedule 13G/A, beneficial ownership, Ordinary Shares, investment adviser, institutional investor, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.